天元醫療(00557.HK)附屬與北京愉悦訂立商標許可協議
格隆匯5月29日丨天元醫療(00557.HK)公佈,在最終審定集團截至2019年12月31日止年度全年業績的過程中,在公司財務團隊的協助下並聽從專業顧問的建議後,董事會方知悉2019年融資協議的貸款金額、2019年商標許可協議的特許權使用費收入以及北京愉悦截至2019年12月31日止年度已向普艾普收取實際營銷費用合共約人民幣660萬元及所構成的非全面豁免關連交易所涉及的實際交易金額。
因此,於2020年5月29日,集團訂立融資協議;商標許可協議及營銷支出協議,從而追認上述截至2019年12月31日止年度的關連交易,並設定特許權使用費收入及營銷費用的年度上限以再次遵守上市規則第14A.54條項下的規定。
於2020年5月29日,珠海天醫(公司間接全資附屬公司)與北京愉悦訂立融資協議。根據融資協議,珠海天醫(作為貸款人)向北京愉悦(作為借款人)提供總額為人民幣300萬元的貸款,按年利率10%計息,自使用之日起為期36個月。
同日,公司非全資附屬公司普艾普與北京愉悦訂立商標許可協議,據此,北京愉悦獲授獨家權利,以於北京就北京愉悦的業務使用DA商標,作為向普艾普支付年度特許權使用費的回報,協議為期三年,於2022年12月31日到期。
此外,普艾普與北京愉悦訂立營銷支出協議,為期三年,於2022年12月30日到期,據此,北京愉悦每年收取固定費用200萬港元,為普艾普於北京推廣及營銷DA品牌以及招攬顧客。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.